Best SARMs for Women? Virilization Risk, Studied Doses and What Research Shows

Search for the best SARMs for women and most answers say the same thing: pick the “mild” ones, keep the dose low, and you will build muscle or lose fat without any masculinizing effects. The research does not support that promise. SARMs (selective androgen receptor modulators) work by activating the androgen receptor, the same receptor testosterone acts on, and androgen receptor activation is what causes virilization in women.

The human data on SARMs in women is thin. Among the SARMs sold for bodybuilding, Ostarine is the only one tested in healthy women, in a 12-week trial of postmenopausal women at 3mg a day or less. A few rarely sold experimental SARMs have small trials in older women, and most of the other data on women comes from cancer trials run under close medical supervision. The doses commonly quoted for women in bodybuilding circles come from forums and vendor guides, not from studies.

This guide covers how SARMs act in a woman’s body, virilization, studied versus reported doses, each compound, and the popular “SARMs for women” that are not SARMs at all. Nothing here is a recommendation to use them.

How SARMs Act in a Woman’s Body

Women produce testosterone too, in the ovaries and adrenal glands, but at roughly a tenth of men’s levels or less. That means a woman’s tissues are not used to strong androgen signals, which is why even modest androgen exposure can cause visible changes.

Testosterone and anabolic steroids act through the androgen receptor. SARMs were developed to activate that receptor strongly in muscle and bone while having much less effect on other tissues (see this review of SARM development). That selectivity was measured mainly in castrated male rats, by comparing the growth of muscle with the growth of the prostate and seminal vesicles. Women have neither organ, and the tissues that matter for virilization (skin, hair follicles, the voice box and the clitoris) were not what those tests measured.

Most SARMs are not steroids, so they are not converted into estrogen or DHT. Their effects come from the androgen receptor itself. “Selective” describes a preference seen in animal tests, not a guarantee that any given tissue in a woman’s body will be spared.

Virilization: The Risk Most Guides Leave Out

Many SARM guides claim that women do not experience virilization on SARMs. No study supports that. No SARM has been tested in healthy young women at bodybuilding doses; the few trials that included women studied older women, mostly after menopause.

Virilization is the development of male-typical traits. The signs most often described with androgen use in women are:

• A hoarse or deeper voice
• New facial or body hair
• Acne and oily skin
• Enlargement of the clitoris
• Thinning scalp hair, especially at the temples and crown
• Irregular or missed periods
• A marked rise in libido

Some of these fade after stopping. Others may not: voice deepening and clitoral enlargement can be permanent. Risk rises with the dose, the potency of the compound, the length of the cycle and the number of androgen-active compounds taken together. Early signs such as hoarseness, new facial hair or sudden acne are a reason to stop and see a doctor.

Studied Doses vs Commonly Reported Doses for Women

The table below sets what research actually used next to the figures that circulate online for women. The reported figures come from forums and vendor guides, not trials. They are not recommendations.

The online figures for women are either above anything tested in healthy women or have no human comparison at all. And the common practice of “pyramiding”, raising the dose week by week, puts the highest exposure at the end of a cycle, when androgen effects have had the longest time to build.

SwissChems Contents6 sections01What Is SwissChems?02Product Range03Top 3 Featured Products04Why It Gets Attention From Fitness Researchers05Testing, Documentation & Regulatory History06Frequently Asked Questions SwissChems is an online research-compound supplier covering SARMs,…

9.2Excellent

Visit SwissChemsBRAWN1010% OFFCopy

Pros

• Exceptional purity & testing (≥98%)
• Pharmaceutical-style packaging for stability
• Broad catalog across peptides & nootropics
• Strong reputation & consistency across years

Cons

• Some items frequently out of stock due to high demand
• Limited long-term data for some compounds

What Is Known About Each Compound

Ostarine (MK-2866, Enobosarm)

Ostarine is the most studied SARM and, among those sold for bodybuilding, the only one with a published trial in healthy women. In a phase 2 trial of 120 healthy older men and postmenopausal women, 3mg a day for 12 weeks increased lean body mass by just over 1kg and improved stair-climbing power compared with placebo. HDL cholesterol fell. A phase 2 trial in men and women with cancer-related muscle loss also found lean mass gains at 1mg and 3mg a day.

That is where the encouraging data ends. Ostarine is not approved for any condition. Two phase 3 trials in lung cancer patients did not meet their main goals, and a placebo-controlled trial in postmenopausal women with stress urinary incontinence did not beat placebo. In women with advanced breast cancer it has been given at 9mg and 18mg a day, because androgen receptor activation can slow some hormone-sensitive breast cancers. Those trials ran under close medical monitoring and say nothing about safety for a healthy woman training in a gym.

Users often call Ostarine the mildest SARM, but that label comes mostly from men, for whom “mild” means less testosterone suppression. The 5-10mg a day commonly quoted for women goes above the 3mg maximum tested in healthy women, and a 12-week trial in older women says little about a younger woman’s voice, skin and cycle.

Ligandrol (LGD-4033)

Online guides often name Ligandrol the best SARM for women because it works at very low doses. That potency is exactly the problem. The only trial in healthy volunteers enrolled 76 men, not women, at 0.1 to 1mg a day for 21 days. At 1mg, lean mass rose by about 1.2kg, while total testosterone, SHBG and HDL cholesterol fell, all within three weeks.

The 1-5mg a day quoted for women has never been tested in women, and 2.5-5mg is several times the highest dose given to healthy men. Published case reports also link LGD-4033 products to drug-induced liver injury. There is no evidence behind calling it a women’s SARM.

Andarine (S4)

Andarine has no published human trial results. In rat studies, including female rats with their ovaries removed as a model of menopause, it preserved bone and lean mass and reduced fat. These are animal data. Users commonly report vision changes, such as a yellow tint and poor night vision, mostly at higher doses. How S4 affects women is simply unknown.

RAD-140 (Testolone)

Even in pro-SARM circles, RAD-140 is rarely suggested for women, because users describe it as one of the more androgenic SARMs. In women it has only been studied in a small phase 1 trial in postmenopausal women with advanced breast cancer, where raised liver enzymes were among the reported side effects. Case reports also describe liver injury in men using RAD-140 products.

YK-11

YK-11 is built on a steroid structure derived from DHT, which makes it more steroid-like than other SARMs. Its “myostatin inhibitor” label comes from cell studies in which it raised follistatin. There are no human trials of any kind.

Rarely Sold SARMs Tested in Older Women

Two experimental SARMs that are rarely sold have small trials that included women. GSK2881078 produced dose-dependent lean mass gains in healthy older men and women. MK-0773, tested in older women with sarcopenia (age-related muscle loss), increased lean mass but did not improve strength or physical function more than placebo. Neither trial looked at young women or bodybuilding doses, and more lean mass on a scan is not the same as more strength.

Not SARMs: Cardarine, SR9009, MK-677 and Myostatin

Several compounds sold alongside SARMs, and often listed among the best SARMs for women, do not act on the androgen receptor at all. They do not cause virilization by themselves, but that does not make them safe.

Cardarine (GW501516)

Cardarine is a PPAR-delta agonist. In mice, it increased fat burning in muscle. GlaxoSmithKline stopped developing it in 2007 after long-term rodent studies found cancers in multiple organs, and WADA took the unusual step of warning athletes about it in 2013. Short human studies of its effect on blood fats used 10mg a day or less. Online plans that build women up to 20mg a day double the doses used in those studies. See Cardarine side effects and cancer risk.

Stenabolic (SR9009)

SR9009 is a REV-ERB agonist, not a SARM. Its fat loss and endurance effects come from mouse studies in which it was injected. It appears to be poorly absorbed by mouth, and there are no human trials.

MK-677 (Ibutamoren, Nutrobal)

MK-677 is an oral growth hormone secretagogue, sometimes sold under the name Nutrobal. Unlike most compounds here, it has real human data, including a 12-month trial in healthy men and women aged 60 to 81. At 25mg a day it raised growth hormone, IGF-1 and fat-free mass, but it also increased appetite and fasting blood sugar and reduced insulin sensitivity.

Myostatin

Myostatin is a protein the body makes to limit muscle growth. It is not a SARM. Lists of “SARMs women should avoid” that include it show how loosely the word SARM is used online.

Periods, Fertility, Pregnancy and Breast Health

Androgen excess is known to disrupt ovulation, and irregular or missed periods are among the effects most commonly reported by women using SARMs. Periods that do not return to normal within a few months of stopping need a doctor’s assessment.

SARMs have not been tested for their effects on fertility, contraception or pregnancy. Androgens taken during pregnancy can masculinize a female fetus, and any compound that activates the androgen receptor should be assumed to carry that risk. Women who are pregnant, trying to conceive or breastfeeding should not use them.

Breast tissue is a special case. Androgen receptor activation can slow some estrogen-receptor-positive breast cancers, which is why Ostarine and RAD-140 have been tested in women with advanced breast cancer. That is a cancer treatment given under medical care, not evidence that SARMs protect healthy breast tissue.

Other SARM Side Effects in Women

• Cholesterol: HDL fell in both the Ostarine trial in older adults and the Ligandrol trial in men. Low HDL is a recognized risk factor for heart disease.
• Liver: Case reports link Ligandrol, RAD-140 and other SARM products to drug-induced liver injury, often with jaundice, appearing within weeks of starting.
• Hair and skin: Acne and scalp hair thinning are commonly reported, especially in women already prone to hair loss.

The FDA has warned that SARMs are linked to serious safety concerns, including liver toxicity and a possible increase in the risk of heart attack and stroke. Product quality adds another unknown: in a study published in JAMA, researchers bought 44 products sold online as SARMs, and only about half contained a SARM at all. Many contained other unapproved drugs or amounts that did not match the label. For more, see the long-term side effects of SARMs.

Stacking SARMs as a Woman

Stacking charts for women still circulate, combining Ostarine, Andarine and Cardarine at up to 20mg a day each. None comes from research. Two androgen receptor activators taken together add to the total androgen load, and so to the virilization risk. A stack also makes it impossible to tell which compound caused a side effect.

Blood Work and Warning Signs

Blood work shows what a compound is doing beneath the surface. The usual panel:

• Hormones: testosterone, SHBG, LH, FSH and estradiol
• Lipids: HDL, LDL and triglycerides
• Liver: ALT, AST and bilirubin
• General: a full blood count

A baseline test gives a reference point. Hoarseness or any voice change, new facial hair, clitoral changes, missed periods, yellowing of the skin or eyes, dark urine or persistent itching are reasons to stop and seek medical advice promptly.

Legal Status and Drug Testing

No SARM is approved for human use in the US or anywhere else. In the US they cannot legally be sold as dietary supplements. WADA bans SARMs and Cardarine at all times, in and out of competition, and anti-doping labs test for them. Rules differ by country; see are SARMs legal for a country list.

Options With Better Evidence for Women

For women who want more muscle or less fat, the approaches with the strongest evidence carry none of the androgen risk. Progressive resistance training is the foundation. Protein matters too: a large meta-analysis found that muscle gains from training levelled off at about 1.6g of protein per kg of body weight a day. Among supplements, creatine monohydrate at 3-5g a day is one of the most studied, including in women.